Search clinical trials for: Interleukin 1 Receptor Antagonist Protein

Total 13002 results

Charles University, Czech Republic
AstraZeneca

Unknown

CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

Czech Republic
Asker & Baerum Hospital
Ullevaal University Hospital; AstraZeneca; Helse Ost

Completed

Candesartan in the Prevention of Relapsing Atrial Fibrillation

Atrial Fibrillation

Norway
Karolinska University Hospital
AstraZeneca

Unknown

Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy

Diabetes, Type I

Sweden
Biogen

Terminated

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency (POSEIDON)

Heart Failure | Renal Insufficiency

United States
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.

Overactive Bladder | Benign Prostatic Hyperplasia (BPH)

Korea, Republic of
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting Conditions

Bioequivalence

Canada
Hvidovre University Hospital

Completed

Incretin Hormone Antagonism After Bariatric Surgery (INCA-BAR)

Bariatric Surgery

Denmark
Christina Kruuse

Recruiting

The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke (EGRABIS1)

Ischemic Stroke

Denmark
Jagiellonian University

Recruiting

Activity of Chronic Inflammation in PCOS

Polycystic Ovary Syndrome

Poland
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

Type 2 Diabetes Mellitus

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Samsung Medical Center

Recruiting

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Breast Cancer | Cardiotoxicity | Prevention | Adjuvant | Trastuzumab

Korea, Republic of
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Cardiorenal Syndrome (CRS)

United States
Takeda

Completed

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Hypertension

Japan
Boehringer Ingelheim

Completed

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Hypertension
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions

Healthy

India
Boehringer Ingelheim

Completed

Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Hypertension
AstraZeneca
Takeda

Completed

DIabetic Retinopathy Candesartan Trials (DIRECT)

Type 2 Diabetes
National Taiwan University Hospital
Daiichi Sankyo Taiwan Ltd.

Completed

Evaluation of Effects of Exercise Training and ARB in DM Patients

Exercise Training | Vascular Function

Taiwan
Novartis

Completed

Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus

Hypertension | Type 2 Diabetes | PROTEINURIA
Novartis

Completed

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Hypertension | Dyslipidemia

Russian Federation
Novartis

Completed

8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension (VANTAGE)

Stage 2 Hypertension

United States
AstraZeneca

Completed

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

Congestive Heart Failure
Gruppo di Ricerca GISSI

Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Atrial Fibrillation

Italy, Switzerland
Novartis Pharmaceuticals

Terminated

A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril

Hypertension | Diabetic Nephropathy

Switzerland
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Forest Laboratories

Completed

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Stage 2 Hypertension | Stage 1 Hypertension

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Irbesartan

Obesity, Morbid

Norway
Takeda

Completed

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Hypertension

Japan
Novartis

Completed

A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age

Hypertension

Germany, United States
Boehringer Ingelheim

Completed

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Hypertension
Boehringer Ingelheim

Completed

Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Hypertension
Boehringer Ingelheim

Completed

Pharmacovigilance and Patient Compliance in Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

BIBR 277 Capsules in Hypertensive Patients With Nephropathy

Hypertension
AstraZeneca

Completed

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)

Congestive Heart Failure
Sanofi
Bristol-Myers Squibb

Completed

Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria (PRIME)

Hypertension
Saitama Medical University
Non-Profit Organaizaion "LINE"

Unknown

Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients

Hypertension

Japan
Jikei University School of Medicine

Unknown

A Morbidity-Mortality and Remodeling Study With Valsartan

Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
Waterstone Hanxbio Pty Ltd

Completed

The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

Advanced Solid Tumor

Australia
Hackensack Meridian Health

Terminated

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

GVHD

United States
The University of Texas Health Science Center,...

Withdrawn

Candesartan as an Adjunctive Treatment for Bipolar Depression

Bipolar Disorder Depression

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Hypertension | Chronic Kidney Disease | Nephrotic Syndrome

Japan
Stanford University

Terminated

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

Hypertension | Insulin Resistance | Dyslipidemia

United States
Augusta University

Unknown

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans (Avapro3)

Hypertension | Obesity | Stress, Psychological | Blood Pressure

United States
Takeda

Completed

A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

Healthy Volunteers

Japan
Takeda

Completed

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Male Participants

Japan
Takeda

Withdrawn

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia. (ALIVE)

Essential Hypertension With Stable Angina and Dyslipidemia

Japan
Takeda

Completed

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Pediatric Hypertension

Japan
Boehringer Ingelheim

Terminated

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Hypertension | Coronary Arteriosclerosis

Germany

3

Subscribe